Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trialShow others and affiliations
2025 (English)In: HemaSphere, E-ISSN 2572-9241, Vol. 9, no 3, article id e70099Article in journal, Letter (Other academic) Published
Place, publisher, year, edition, pages
John Wiley & Sons, 2025. Vol. 9, no 3, article id e70099
National Category
Cancer and Oncology Hematology
Identifiers
URN: urn:nbn:se:uu:diva-554599DOI: 10.1002/hem3.70099ISI: 001449707300001PubMedID: 40124718Scopus ID: 2-s2.0-105000545482OAI: oai:DiVA.org:uu-554599DiVA, id: diva2:1952283
2025-04-152025-04-152025-04-15Bibliographically approved